{"id":"NCT01644188","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","officialTitle":"A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2014-05","completion":"2015-07","firstPosted":"2012-07-18","resultsPosted":"2015-11-06","lastUpdate":"2016-08-04"},"enrollment":720,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["REGN727/SAR236553","Praluent"]},{"type":"DRUG","name":"Placebo (for alirocumab)","otherNames":[]},{"type":"DRUG","name":"Ezetimibe","otherNames":[]},{"type":"DRUG","name":"Placebo (for ezetimibe)","otherNames":[]},{"type":"DRUG","name":"Lipid Modifying Therapy (LMT)","otherNames":[]}],"arms":[{"label":"Alirocumab 75 /up to 150 mg Q2W","type":"EXPERIMENTAL"},{"label":"Ezetimibe 10 mg","type":"ACTIVE_COMPARATOR"}],"summary":"Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).\n\nPrimary Objective of the study:\n\nTo demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy in comparison with ezetimibe after 24 weeks of treatment in participants with hypercholesterolemia at high cardiovascular (CV) risk.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab in comparison with ezetimibe on LDL-C at other time points\n* To evaluate the effect of alirocumab on other lipid parameters\n* To evaluate the safety and tolerability of alirocumab","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis","timeFrame":"From Baseline to Week 52","effectByArm":[{"arm":"Alirocumab 75 /up to 150 mg Q2W","deltaMin":-50.6,"sd":1.4},{"arm":"Ezetimibe 10 mg","deltaMin":-20.7,"sd":1.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":5},"locations":{"siteCount":126,"countries":["United States","Canada","Denmark","France","Hungary","Israel","Russia","South Africa","South Korea","Ukraine"]},"refs":{"pmids":["25240705","25687353","34298554","30183102","27777279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":124,"n":479},"commonTop":["Accidental overdose","Upper respiratory tract infection","Dizziness","Hypertension","Headache"]}}